Nope, only the experts on the Data Safety Monitoring Board have access to unblinded data to monitor safety and they aren't telling. The company is blind until the trial is complete, the data will be sent to an independent expert in statistics (maybe at a university) for evaluation and the results of the analysis sent to the company to announce.
All they've seen are the overall blinded results of the combined treatment data which they can compare with the overall results of the phase 2 trial. You can't really say much except that hopefully the phase 3 trial will mirror the phase 2 trial.
We've placed a bet based on the strength of the phase 2 trial results so we now just have to wait and hope.
Hang in there!!, page-149
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $240.2M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.5¢ | 36.0¢ | $774.7K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 133753 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 468759 | 15 |
View Market Depth
| Last trade - 15.42pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
36.5¢ |
Change
0.000 ( 1.43 %) |
||||
| Open | High | Low | Volume | ||
| 36.5¢ | 37.0¢ | 36.0¢ | 890870 | ||
| Last updated 15.55pm 17/06/2024 ? | |||||
| OPT (ASX) Chart |
